Balance Sheet
Cash Flow Statement
AcquisitionsAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsCash from RestructuringChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Dividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Innospec (IOSP) Other financing activities (2016 - 2025)

Historic Other financing activities for Innospec (IOSP) over the last 15 years, with Q3 2025 value amounting to -$200000.0.

  • Innospec's Other financing activities fell 12222.22% to -$200000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $1.7 million, marking a year-over-year change of 0.0%. This contributed to the annual value of $2.4 million for FY2024, which is 7142.86% up from last year.
  • As of Q3 2025, Innospec's Other financing activities stood at -$200000.0, which was down 12222.22% from $400000.0 recorded in Q2 2025.
  • In the past 5 years, Innospec's Other financing activities ranged from a high of $1.9 million in Q3 2022 and a low of -$200000.0 during Q3 2025
  • In the last 5 years, Innospec's Other financing activities had a median value of $500000.0 in 2024 and averaged $558333.3.
  • In the last 5 years, Innospec's Other financing activities soared by 100000.0% in 2024 and then crashed by 12222.22% in 2025.
  • Innospec's Other financing activities (Quarter) stood at $100000.0 in 2021, then tumbled by 200.0% to -$100000.0 in 2022, then changed by 0.0% to -$100000.0 in 2023, then soared by 800.0% to $700000.0 in 2024, then crashed by 128.57% to -$200000.0 in 2025.
  • Its Other financing activities stands at -$200000.0 for Q3 2025, versus $400000.0 for Q2 2025 and $800000.0 for Q1 2025.